Celtic Therapeutics sets up $50m antibody drug company

The investment will provide financial support for the new company throughout pre-clinical trials within the coming 12 months, and bring it into clinical trials within the next two years. Once ADC reaches phase II of clinical trials, the company will seek to build commercial relations for marketing and distribution of the products.

Company
ADC Therapeutics is a pharmaceuticals company based in Lausanne, Switzerland that focuses on the development of oncology drugs. Its products aim to have fewer side effects and to be targeted more accurately due to the use of cytotoxic warheads, developed by UK-based company Spirogen Ltd. The company is currently developing ten products.

People
Michael Forer is CEO of ADC Therapeutics and partner at Celtic Therapeutics. He will be joined on the board of directors by Peter Corr and Stephen Evans-Freke, co-founders of Celtic Therapeutics, and Christoper Martin, CEO of Spirogen. 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Now researching
• Switzerland